Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

NCT00509379 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Non-Hodgkin Lymphoma

Interventions

DRUG: Rituximab
DRUG: VELCADE

Sponsor

Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

Collaborators

[object Object]
[object Object]
[object Object]